Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | TOP1 | P11387 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252132 | 0.84 | ACHE (0.43) | ACHELMNATSHRALOX12TDP1 | |
| SCHEMBL5680509 | 0.83 | ACHE (0.33) | ACHE | |
| SCHEMBL4659378 | 0.82 | CYP3A4 (0.52) | TDP1CYP3A4DRD1ESR1ESR2 | |
| Water SCHEMBL28398548 | 0.80 | CYP3A4 (0.50) | TDP1CYP3A4DRD1ESR1ESR2 | |
| SCHEMBL9016341 | 0.78 | LMNA (0.38) | ACHELMNATSHRALOX12TDP1 | |
| SCHEMBL16760866 | 0.75 | TDP1 (0.44) | ACHELMNATSHRALOX12TDP1 | |
| SCHEMBL15623199 | 0.75 | ACHE (0.35) | ACHELMNATSHRALOX12TDP1 | |
| SCHEMBL1683360 | 0.75 | ALDH1A1 (0.39) | ACHELMNATSHRALOX12TDP1 | |
| SCHEMBL23590181 | 0.73 | MEN1 (0.34) | ACHELMNATSHRALOX12TDP1 | |
| SCHEMBL5570256 | 0.72 | TDP1 (0.40) | ACHELMNATSHRALOX12TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334976-B1 | Novel phosphine compound, transition metal complex containing said compound as ligand and asymetric synthesis catalyst containing said complex | TAKASAGO PERFUMERY CO LTD (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-6717016-B2 | HAVING CHEMICAL SELECTIVITY, ENANTIOSELECTIVITY, CATALYTIC ACTIVITY; FOR USE AS A CATALYST FOR ASYMMETRIC SYNTHESES, ESPECIALLY ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-04-06 | — | — | US | disclosed |
| EP-1334976-A1 | Novel phosphine compound, transition metal complex containing said compound as ligand and asymetric synthesis catalyst containing said complex | Takasago International Corporation (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20030144139-A1 | Novel phosphine compound, transition metal complex containing the same phosphine compound as ligand and asymmetric synthesis catalyst containing the complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144139-A1 | Novel phosphine compound, transition metal complex containing the same phosphine compound as ligand and asymmetric synthesis catalyst containing the complex | PHOSPHO1, MEN1, PDCD1 | ACHE 1073/4885LMNA 4812/4885TSHR 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.